Jin‐Hyoung Kang

3.5k total citations · 1 hit paper
98 papers, 2.2k citations indexed

About

Jin‐Hyoung Kang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jin‐Hyoung Kang has authored 98 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Pulmonary and Respiratory Medicine, 64 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in Jin‐Hyoung Kang's work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (24 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Jin‐Hyoung Kang is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (24 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Jin‐Hyoung Kang collaborates with scholars based in South Korea, China and United States. Jin‐Hyoung Kang's co-authors include Yeon‐Sil Kim, Toyoaki Hida, Makoto Nishio, Ji‐Youn Han, Hiun‐Suk Chae, Suk Kyeong Lee, Helen Mann, Lyudmila Bazhenova, Quincy S. Chu and Gee‐Chen Chang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Jin‐Hyoung Kang

91 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

2016 502 citations Quincy S. Chu, Toyoaki Hida et al. profile →

Peers

Countries citing papers authored by Jin‐Hyoung Kang

Since Specialization

Citations

This map shows the geographic impact of Jin‐Hyoung Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin‐Hyoung Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin‐Hyoung Kang more than expected).

Fields of papers citing papers by Jin‐Hyoung Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin‐Hyoung Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin‐Hyoung Kang. The network helps show where Jin‐Hyoung Kang may publish in the future.

Co-authorship network of co-authors of Jin‐Hyoung Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Jin‐Hyoung Kang. A scholar is included among the top collaborators of Jin‐Hyoung Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin‐Hyoung Kang. Jin‐Hyoung Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial 2024 ·Journal of Thoracic Oncology ·John V. Heymach, David Harpole, (unknown), Janis M. Taube, Shugeng Gao, László Urbán, Jin‐Hyoung Kang, Francesco Orlandi, Jerónimo Rafael Rodríguez‐Cid, Bartomeu Massutí, (unknown), Giulia Pasello, Quincy S. Chu, Jarosław Kołb-Sielecki, (unknown), Mike Aperghis, Helen Mann, Tamer M. Fouad, Gary J. Doherty, Martin Reck	5
2	KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS ^G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC. 2023 ·Journal of Clinical Oncology ·Federico Cappuzzo, Gilberto de Castro, Jin‐Hyoung Kang, Yi‐Long Wu, Odd Terje Brustugun, Parneet Cheema, Taofeek K. Owonikoko, (unknown), Aislyn Boran, (unknown), (unknown), Herbert H. Loong	8
3	A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy 2023 ·Cancer Research and Treatment ·Young‐Woong Won, Jin‐Hyoung Kang, Jung Hye Kwon, Dong‐Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae‐Won Lee, Joohyuk Sohn, Sarah Soyeon Oh, Kyung Hee Lee, Su‐Jin Koh, Keun Seok Lee, Chan Kyu Kim, Jiyeon Kim, Jun Ho Ji, Sung‐Bae Kim, (unknown), Ho Young Kim	1
4	Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer 2021 ·Annals of Oncology ·Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, K.H. Lee, Takamasa Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Yoshinobu Namba, (unknown), Kazuhiko Nakagawa	135
5	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer 2020 ·Frontiers in Oncology ·Jin‐Hyoung Kang, Xu‐Chao Zhang, Hua‐Jun Chen, Wen‐Zhao Zhong, Yang Xu, Jian Su, Qing Zhou, Hai‐Yan Tu, Zhen Wang, Chong‐Rui Xu, Xue‐Ning Yang, Zhihong Chen, Xue Wu, Xian Zhang, (unknown), Yi‐Long Wu, Jin‐Ji Yang	27
6	TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer 2019 ·Translational Lung Cancer Research ·(unknown), Yuanyuan Lei, Jian Su, Chao Zhang, Rui Fu, Jin‐Hyoung Kang, Hong‐Hong Yan, Xue‐Ning Yang, Hai‐Yan Tu, Yi‐Long Wu, Wen‐Zhao Zhong	8
7	Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer 2018 ·Thoracic Cancer ·Jin‐Hyoung Kang, Hua‐Jun Chen, Xu‐Chao Zhang, Jian Su, Qing Zhou, Hai‐Yan Tu, Zhen Wang, (unknown), Wen‐Zhao Zhong, Xue‐Ning Yang, Zhihong Chen, Yan Ding, Xue Wu, Mei Wang, Jiangang Fu, Zhenfan Yang, Xian Zhang, Yang Shao, Yi‐Long Wu, Jin‐Ji Yang	17
8	Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study 2018 ·Supportive Care in Cancer ·Jeevendra Kanagalingam, (unknown), Jin‐Ching Lin, (unknown), (unknown), Jin‐Hyoung Kang, Shouki Bazarbashi, (unknown), (unknown), Stefan C. Mueller, Hanlim Moon	16
9	EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib 2018 ·Journal of Thoracic Oncology ·Qi Zhang, Xu‐Chao Zhang, Jin‐Ji Yang, Zhenfan Yang, Yu Bai, Jian Su, Zheng Wang, Zhou Zhang, Yang Shao, Qing Zhou, Jin‐Hyoung Kang, E‐E Ke, Yichen Zhang, Zhong‐Yi Dong, Zhihong Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu	56
10	Co-occurring alterations in driver genes impact on EGFR-targeted therapy among patients with EGFR-mutant advanced non–small cell lung cancer 2018 ·Annals of Oncology ·Chang Lu, Jin‐Hyoung Kang, (unknown), Hai‐Yan Tu, Qing Zhou, (unknown), Yi‐Long Wu, Jin‐Ji Yang	1
11	High-Dose Thoracic Re-irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective with Acceptable Toxicity 2018 ·Cancer Research and Treatment ·(unknown), Yeon‐Sil Kim, Sea-Won Lee, So Jung Lee, Jin‐Hyoung Kang, (unknown), (unknown), (unknown)	12
12	Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer 2018 ·Journal of Neuro-Oncology ·(unknown), Sea-Won Lee, (unknown), Jin‐Hyoung Kang, Sook Hee Hong, Yeon‐Sil Kim	21
13	Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program 2018 ·Oncology ·Sook Hee Hong, Ho Jung An, Ki Hwan Kim, (unknown), Yun‐Gyoo Lee, (unknown), (unknown), Yee Soo Chae, (unknown), Jin‐Hyoung Kang	5
14	Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis 2015 ·Cancer Research and Treatment ·Yun Hee Lee, Yeon‐Sil Kim, Sang Nam Lee, (unknown), Se Jin Oh, (unknown), Young Kyoon Kim, Dae Hee Han, Ie Ryung Yoo, Jin‐Hyoung Kang, (unknown)	44
15	Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes 2013 ·International Journal of Oncology ·Jieun Oh, (unknown), (unknown), Xianghua Zhang, Hye‐Sung Won, Sang Hoon Chun, Chan Kwon Jung, (unknown), (unknown), (unknown), Jin‐Hyoung Kang	15
16	Long-term clinical experience of high-dose ablative lung radiotherapy: High pre-treatment [18F]Fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome 2013 ·Lung Cancer ·Dong Soo Lee, Yeon‐Sil Kim, Ie Ryung Yoo, Young Nam Kang, (unknown), Jin Kyung Oh, Young Kyoon Kim, Young Pil Wang, (unknown), Jin‐Hyoung Kang, Dae Hee Han, (unknown), Kyo Young Lee	20
17	A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS 2013 ·Cancer Biology & Therapy ·Xianghua Zhang, Ying Cheng, (unknown), (unknown), Jieun Oh, Jin‐Hyoung Kang	27
18	A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy 2013 ·Lung Cancer ·Jin Seok Ahn, Ki Hyeong Lee, Jong‐Mu Sun, Keunchil Park, Eun‐Suk Kang, Eun Kyung Cho, Dae Ho Lee, Sang‐We Kim, Gyeong‐Won Lee, Jin‐Hyoung Kang, Jong Seok Lee, Jae‐Won Lee, Myung‐Ju Ahn	26
19	Metastatic collecting duct (Bellini duct) carcinoma: A case report 2009 ·The Korean Journal of Internal Medicine ·(unknown), (unknown), Jin‐Hyoung Kang, (unknown), (unknown), (unknown), (unknown)	1
20	Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group 2009 ·Journal of Thoracic Oncology ·Ji Eun Uhm, (unknown), Myung‐Ju Ahn, Jeeyun Lee, Jin Seok Ahn, (unknown), Heung-Tae Kim, (unknown), Jin‐Hyoung Kang, Y. Choi, Hong Song, Se Hoon Park, (unknown), Sang Won Shin, (unknown), Keunchil Park	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact